Spots Global Cancer Trial Database for Optimal Treatment Strategy Based on for Pediatric AML
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Optimal Treatment Strategy Based on for Pediatric AML
Official Title: Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia
Study ID: NCT02848183
Conditions
Study Description
Brief Summary: The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)
Detailed Description: I. Risk group assessment Favorable prognosis group: Low risk features + Good response Intermediate prognosis group: 1. Low risk features + Delayed response-1 2. Standard risk features + Good response 3. Standard risk features + Delayed response-1 Poor prognosis group: 1. Any high risk features irrespective of treatment response 2. Any delayed response-2 irrespective of risk features 3. Any refractory state irrespective of risk features 4. Any early relapse II. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide III. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chonnam National University Hwasun Hospital, Chonnam, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
St. Mary Hospital, Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
